-
Your prediction
Bellicum Pharmaceuticals Inc. Stock
Pros and Cons of Bellicum Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Bellicum Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bellicum Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | -0.620% | -12.086% | -15.475% | 35.391% | 4.706% | -16.524% | - |
| Salarius Pharmaceuticals Inc. | 1.850% | 10.553% | -19.266% | -71.613% | -20.721% | -98.176% | -99.994% |
| Evolus Inc | -1.830% | -7.627% | -15.504% | 39.744% | 16.578% | 15.344% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Bellicum Pharma (ticker symbol: BLCM), a biotechnology and medical research company, has shown mixed financial performance over the last three years. While certain elements of their financials may be positioned for potential improvements and growth opportunities, there are undoubtedly areas of concern that need to be seriously considered by investors.
Net Working Capital: The net working capital for Bellicum Pharma has increased from 14.74 million in 2020 to 20.03 million in 2022. This may suggest the company's ability to cover its short-term obligations has improved over time, which is a positive sign for potential investors.
Lower Research and Development Costs: In Q4 2022, the company's research and development (R&D) expenses were 6.34 million, while in FY 2020, it was 39.05 million. A decrease in R&D expenditure might signify improved efficiency in research, and the company may be focusing on projects with higher potential returns.
Comments
